Tauroursodeoxycholate-d4
For Laboratory Research Only. Not for Clinical or Personal Use.
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Tauroursodeoxycholate-d4
Description :
Tauroursodeoxycholate-d4 is deuterium labeled Tauroursodeoxycholate. Tauroursodeoxycholate (Tauroursodeoxycholic acid) is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK.Product Name Alternative :
Tauroursodeoxycholic acid-d4; TUDCA-d4; UR 906-d4UNSPSC :
12352211Hazard Statement :
H225, H370Target :
Apoptosis; Caspase; Endogenous Metabolite; ERK; Isotope-Labeled CompoundsType :
Isotope-Labeled CompoundsRelated Pathways :
Apoptosis; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Others; Stem Cell/WntApplications :
Cancer-Kinase/proteaseField of Research :
CancerConcentration :
198.52 μM * 1 mL in MethanolPurity :
99.7Solubility :
10 mM in DMSOSmiles :
O=S(CCNC(CC[C@H]([C@H]1CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C([2H])([2H])[C@H](O)C([2H])([2H])C[C@]4(C)[C@@]3([H])CC[C@]12C)C)=O)(O)=OMolecular Formula :
C26H41D4NO6SMolecular Weight :
503.73Precautions :
H225, H370References & Citations :
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Kim SY, et al. Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression of ERK viaPKCα-mediated MKP-1 induction. Cardiovasc Res. 2011 Nov 1;92 (2) :307-16.|[3]Qin Y, et al. Tauroursodeoxycholic Acid Attenuates Angiotensin II Induced Abdominal Aortic Aneurysm Formation in Apolipoprotein E-deficient Mice by Inhibiting Endoplasmic Reticulum Stress. Eur J Vasc Endovasc Surg. 2017 Mar;53 (3) :337-345.Shipping Conditions :
Blue IceStorage Conditions :
Solution, -20°C, 2 yearsScientific Category :
Isotope-Labeled CompoundsClinical Information :
No Development ReportedCAS Number :
[2410279-94-4]

